Back to top

Analyst Blog

AVEO Oncology (AVEO - Snapshot Report) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB - Analyst Report).

We note that AVEO was developing oncology candidate AV-203 in collaboration with Biogen which had an option to develop the candidate outside the United States. The collaboration dates back to 2009 whereby AVEO retained the exclusive rights to commercialize AV-203 in North America.

AVEO completed a phase I safety study on AV-203 in May 2013.  AVEO expects to report results from the phase I study at a scientific meeting later in 2014.

Under the terms of the amended agreement, Biogen renounced its rights to develop and commercialize AV-203 outside North America.

AVEO has several other candidates in its pipeline including ficlatuzumab (phase II – first line non-small cell lung cancer), AV-380 (first human trial planned for the second half of 2015 – cancer cachexia) and tivozanib.  

We note that AVEO and partner Astellas Pharma, Inc. (ALPMY) announced their decision to terminate their agreement for the development and commercialization of oncology candidate, tivozanib in Feb 2014. The worldwide collaboration and license agreement, which dates back to 2011, will come to an end on Aug 11, 2014, with full rights to tivozanib going back to AVEO.

AVEO is now actively looking for a partner to support the development of AV-203, ficlatuzumab and tivozanib. We expect investor focus on the company’s ability to secure a lucrative partnership deal for its various candidates.
 
AVEO carries a Zacks Rank #3 (Hold). A better-ranked stock is Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) carrying a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 114.46 +5.95%
LANNETT COM… LCI 40.60 +3.26%
ERBA DIAGNO… ERB 3.87 +1.84%
US SILICA H… SLCA 69.00 +1.47%
GENTIVA HEA… GTIV 18.02 +1.41%